Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
16 Total results for product and free and sample content found
Pink Sheet
By Michael McCaughan 16 Jun 2022
The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.
Topic US Election 2020
Medtech Insight
By Sue Darcey 16 Jun 2022
Out of 31 US House incumbents supported by high amounts of medtech industry political action committee (PAC) dollars, only one – Chrissy Houlahan of Pennsylvania – lost in last week’s election.
Medtech Insight
By Sue Darcey 18 Nov 2020
A few of the US Senate candidates favored and given tens of thousands of dollars by industry have lost their battles for re-election
Topic US Election 2020 Legislation
Pink Sheet
By Cathy Kelly 18 Nov 2020
A Biden Administration with near-term priorities other than drug pricing and a Republican-controlled Senate dedicated to blocking any legislation that would enact government price controls is a relatively positive outcome for industry
Topic US Election 2020 Drug Pricing
Pink Sheet
By Cathy Kelly 17 Nov 2020
Germany uses government facilitated price negotiations between publicly funded insurers and manufacturers that are based on an independent assessment of how much added value a drug provides.
Topic US Election 2020 Drug Pricing
Pink Sheet
By Joseph Haas 29 Oct 2020
EUA request for COVID-19 vaccine is unlikely before late November; the CEO’s frequent comments that the timetable isn’t politically motivated are unusual to say the least
Pink Sheet
By Sarah Karlin-Smith 21 Oct 2020
Company may have violated FDA’s preapproval promotion restrictions by discussing compassionate use option with Joe Biden’s team and by publicizing it on TV, highlighting the fine line between making the general public aware of expanded access and touting an investigational product as useful for a particular illness.
Topic Coronavirus Advertising, Marketing & Sales US Election 2020
Pink Sheet, Scrip
By Sarah Karlin-Smith 09 Oct 2020
Trump receives Regeneron’s experimental antibody under FDA’s expanded access program, Gilead’s remdesivir and dexamethasone. The president’s treatment choices could influence clinical trials of all COVID-19 medicines and even trial recruitment for other diseases, experts said.
Generics Bulletin
By Akriti Seth 25 Sep 2020
The AAM has published a timely guide highlighting various voter issues of concern in the run-up to the US elections, including anti-competitive tactics building on monopoly pricing and weak patent laws. The AAM has also called for policies to encourage generic and biosimilar entry in the market while the guide also focuses on policies around the US supply chain.
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
